Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Oral Cavity Cancer
NCT03721757Phase 2Completed
- Start
- May 2019
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in squamous cell carcinoma of the oral cavity (OSCC). Started May 2019; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)
Beyond the preview
Go deeper on NCT03721757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721757.